In a recent study, a risk model based in inverse SOX2/SOX9 expression also identified EGFR signaling as a candidate for HNSCC patients with SOX2 low and SOX9 high expression pattern [41]. The gene discussed is SOX9; the disease is head and neck squamous cell carcinoma.